# Elacestrant in ER+, HER2− Metastatic Breast Cancer with <i>ESR1</i> -Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups

*PRI Rank #4 · Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026/rank-4*

| Field | Value |
| --- | --- |
| Rank | #4 |
| 18m citations | 64 |
| Journal | Clinical Cancer Research |
| Year | 2024 |
| DOI | 10.1158/1078-0432.ccr-24-1073 |
| Corresponding authors | Aditya Bardia |
| Institution | University of California Los Angeles, United States |

**Ranking page:** [Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026](https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026)

**Paper link:** [10.1158/1078-0432.ccr-24-1073](https://doi.org/10.1158/1078-0432.ccr-24-1073)

## Topics

elacestrant · ESR1 mutation · ER+ HER2- metastatic breast cancer · CDK4/6 inhibitor · EMERALD trial · Progression-free survival · resistance · fulvestrant · aromatase inhibitor · ESR1 D538G mutation · ESR1 Y537S/N mutation · PIK3CA mutation · TP53 mutation · HER2-low · Bone metastases · liver and lung metastases · prior treatment duration · selective estrogen receptor degrader

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026. https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026. Accessed 2026-07-31.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```